Important Updates

TrialNet Statement

Date: 3/13/2019

As a result of decreased funding, TrialNet is required to make difficult decisions to ensure we keep moving successfully toward our mission of preventing type 1 diabetes (T1D).

Using knowledge gained through clinical research, TrialNet’s mission is to prevent T1D and stop disease progression by preserving insulin production before and after diagnosis. After careful consideration of many years of data collected from the Pathway to Prevention risk screening study, we are making the following changes:

TrialNet will no longer offer routine annual rescreening to children who initially screen negative for autoantibodies. Additionally, TrialNet has increased the age of entry into the Pathway to Prevention study from 1 year to 2.5 years old (age of entry for participants in the UK will remain at 3 years old).

We realize that these changes may be disappointing. TrialNet will continue to offer critical T1D prevention trials to participants who test positive for autoantibodies.

Our participants are the foundation for research advancements, and participating in TrialNet is more important than ever.  We want to thank all of our participants for your continued support and dedication to important T1D research.

Please continue to follow our Facebook posts for additional information about these and other upcoming changes. If you have questions or concerns, please contact your study team or